Latest From Ophthotech Corp.
In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.
Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.
Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health
This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Ophthotech Corp.
- Senior Management
Glenn P Sblendorio, Pres. & CEO
David F Carroll, CFO
Kourous A Rezaei, MD, SVP, CMO
- Contact Info
Phone: (212) 845-8200
One Penn Plaza, Ste. 3520
New York, NY 10119
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.